MIRA Pharmaceuticals files Phase 2a trial protocol for CIPN drug

June 17, 2026 8:00 AM

MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) has submitted a Phase 2a clinical trial protocol to the U.S. Food and Drug Administration ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found